RegeneRx is developing RGN-457 as a novel inhaled (via nebulization) treatment for cystic fibrosis and bronchiectasis. RGN-457’s anti-inflammatory and mucolytic properties make it a unique therapeutic candidate for both of these pulmonary orphan diseases. Preclinical studies have indicated that RGN-457 reduces sputum length and cohesivity by depolymerizing and inhibiting f-actin formation in sputum.

RegeneRx has conducted multiple preclinical studies to date in preparation for an FDA IND filing.

	Cystic Fibrosis Bronchiectasis